Thyroid-Like Ophthalmopathy in a Euthyroid Patient Receiving Ipilimumab
- 10 September 2014
- journal article
- case report
- Published by Informa UK Limited in Orbit
- Vol. 33 (6), 424-427
- https://doi.org/10.3109/01676830.2014.949792
Abstract
A 68-year-old lady with metastatic malignant melanoma was treated with Ipilimumab. She presented to Eye Casualty unable to move her eyes. Physical examination confirmed ophthalmoplegia and identified proptosis bilaterally. Radiological imaging showed bilateral enlargement of all the extra-ocular muscles suggestive of thyroid eye disease. Laboratory investigations found this patient to be euthyroid. A diagnosis of thyroid-like orbitopathy secondary to Ipilimumab therapy was made. Thyroid function tests should be performed for all patients prior to their commencement of Ipilimumab. Thyroid-like eye disease may develop in patients treated with Ipilimumab even if they remain euthyroid.Keywords
This publication has 16 references indexed in Scilit:
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institutionEndocrine-Related Cancer, 2014
- Myosite orbitaire associée à un traitement par ipilimumabAnnales de Dermatologie et de Vénéréologie, 2013
- Drug-Induced Graves Disease From CTLA-4 Receptor SuppressionOphthalmic Plastic & Reconstructive Surgery, 2011
- Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapyActa Endocrinologica, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Graves' OphthalmopathyThe New England Journal of Medicine, 2010
- Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypesPituitary, 2009
- Cytotoxic T-Lymphocyte-Associated Antigen-4 Blockage Can Induce Autoimmune Hypophysitis in Patients With Metastatic Melanoma and Renal CancerJournal of Immunotherapy, 2005
- Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4Journal of Clinical Oncology, 2005
- CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor ImmunotherapyAnnual Review of Immunology, 2001